Description
The abstract shows DSS improves AD symptoms via energy metabolism regulation while noting Aβ-targeting therapies have been unsuccessful clinically. The mechanistic basis for why energy metabolism intervention succeeds where Aβ approaches fail remains unexplained, which is critical for understanding alternative AD therapeutic strategies.
Gap type: unexplained_observation Source paper: Unveiling the molecular mechanisms of Danggui-Shaoyao-San against Alzheimer’s disease in APP/PS1 mice via integrating proteomic and metabolomic approaches. (2024, Alzheimer’s research & therapy, PMID:39563386)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:28.154602+00:00”, “resolution_summary”: “Resolved by hypothesis hyp-SDA-2026-04-12-20260411-082446-2c1c9e2d-1: Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Partially Irreversible. Supporting evidence includes debate sess_SDA-2026-04-15-gap-pubmed-20260411-083737-59771b32_20260416-033540.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “hyp-SDA-2026-04-12-20260411-082446-2c1c9e2d-1”, “title”: “Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Partially Irreversible”, “score”: 0.229, “reason”: “25 token overlaps; entity overlap: app”, “analysis_id”: “SDA-2026-04-12-20260411-082446-2c1c9e2d”, “target_gene”: “APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis)”, “target_pathway”: “Cholinergic signaling pathway”, “disease”: null, “composite_score”: 0.887, “confidence_score”: 0.75, “status”: “debated”, “pubmed_evidence_ids”: [“12450488”, “18220527”, “26813123”, “26923405”, “27670619”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-083737-59771b32_20260416-033540”, “title”: “The study demonstrates that SGMS1 elevation correlates with increased Aβ and that SGMS inhibition reduces Aβ production, but the specific biochemical pathways connecting sphingomyelin metabolism to APP processing remain unexplained. Understanding this mechanism is critical for developing targeted therapeutic interventions.\n\nGap type: unexplained_observation\nSource paper: Elevation in sphingomyelin synthase activity is associated with increases in amyloid-beta peptide generation. (None, None, PMID:23977395)”, “score”: 0.51, “reason”: “11 token overlaps; entity overlap: app, pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-083737-59771b32”, “quality_score”: 0.75, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c_task_9aae8fc5”, “title”: “The abstract identifies that neurons show resistance to autophagy induction, but the mechanistic basis remains incompletely defined. Understanding this resistance is crucial for developing neuron-targeted autophagy therapies for ALS.\n\nGap type: unexplained_observation\nSource paper: Autophagy and ALS: mechanistic insights and therapeutic implications. (2022, Autophagy, PMID:34057020)”, “score”: 0.454, “reason”: “12 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-145358-185db2c8_20260414-005137”, “title”: “The study shows homozygous R136S fully rescues APOE4-driven pathology while heterozygous provides only partial protection, but the mechanistic basis for this gene dosage effect is unexplained. Understanding this mechanism is critical for developing therapeutic strategies that could mimic R136S protection.\n\nGap type: unexplained_observation\nSource paper: The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. (2023, Nature neuroscience, PMID:37957317)”, “score”: 0.439, “reason”: “13 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-145358-185db2c8”, “quality_score”: 0.81, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-183021-c13d9f04”, “title”: “The abstract describes astrocyte phenotypic heterogeneity (A1/A2) but doesn’t explain the mechanistic switches governing this critical fate decision. Understanding these mechanisms is essential for therapeutic targeting of beneficial vs harmful astrocyte responses.\n\nGap type: unexplained_observation\nSource paper: Contribution of astrocytes to neuropathology of neurodegenerative diseases. (2021, Brain research, PMID:33516810)”, “score”: 0.421, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-183021-c13d9f04”, “quality_score”: 0.66, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260411-075338-35f913fb”, “title”: “The abstract shows HDAC9 overexpression reduces Aβ deposition and improves synaptic deficits, but the underlying molecular pathways are not explained. Understanding these mechanisms is critical for developing HDAC9-targeted therapeutics for AD.\n\nGap type: unexplained_observation\nSource paper: Neuronal HDAC9: A key regulator of cognitive and synaptic aging, rescuing Alzheimer’s disease-related phenotypes. (2026, Mol Psychiatry, PMID:41935184)”, “score”: 0.416, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260411-075338-35f913fb”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}